Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization

被引:5
作者
Behar-Cohen, Francine [1 ,2 ,3 ,5 ]
Dernigoghossian, Marilyn [1 ,2 ,3 ]
Andrieu-Soler, Charlotte [1 ,4 ]
Levy, Rinath [1 ,2 ,3 ]
Cohen, Raphael [1 ,2 ,3 ]
Zhao, Min [1 ,2 ,3 ]
机构
[1] Ctr Rech Cordeliers, INSERM, UMR S 1138, Team 17, Paris, France
[2] Univ Paris 06, Sorbonne Univ, Ctr Rech Cordeliers, UMR S 1138, Paris, France
[3] Paris Descartes Univ, Sorbonne Paris Cite, Ctr Rech Cordeliers, UMR S 1138, Paris, France
[4] Univ Montpellier, CNRS, IGMM, Montpellier, France
[5] Ophtalmopole Hop Cohin, AP HP, Paris, France
关键词
MACULAR DEGENERATION; BARRIER BREAKDOWN; RANIBIZUMAB; PHARMACOKINETICS; BEVACIZUMAB; EXPRESSION; PRIMATE; DRUGS; EDEMA;
D O I
10.1016/j.drudis.2019.05.034
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The intravitreous injection of therapeutic proteins that neutralize vascular endothelial growth factor (VEGF) family members is efficient to reduce macular edema associated with wet age-related macular degeneration (AMD), retinal vein occlusion (RVO) and diabetic retinopathy (DR). It has revolutionized the visual prognosis of patients with macular edema. The antiedematous effect is dependent on an intravitreous dose of drug, which varies between patients and requires frequent and repeated injections to maintain its effects. At the time when optimizing the duration of anti-VEGF effects is a major challenge, understanding how anti-VEGF reduces macular edema is crucial. We discuss herein how antiVEGF exerts antiedematous effects and raise the hypothesis that mechanisms, unrelated to VEGF neutralization, might have been underestimated.
引用
收藏
页码:1436 / 1439
页数:4
相关论文
共 30 条
[1]  
Behar-Cohen F., 2019, Patent No. [WO2019043179, 2019043179]
[2]   Pro-permeability Factors in Diabetic Macular Edema; the Diabetic Macular Edema Treated With Ozurdex Trial [J].
Campochiaro, Peter A. ;
Hafiz, Gulnar ;
Mir, Tahreem A. ;
Scott, Adrienne W. ;
Zimmer-Galler, Ingrid ;
Shah, Syed M. ;
Wenick, Adam S. ;
Brady, Christopher J. ;
Han, Ian ;
He, Lingmin ;
Channa, Roomasa ;
Poon, David ;
Meyerle, Catherine ;
Aronow, Mary Beth ;
Sodhi, Akrit ;
Handa, James T. ;
Kherani, Saleema ;
Han, Yong ;
Sophie, Raafay ;
Wang, Guohua ;
Qian, Jiang .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2016, 168 :13-23
[3]   Histologic localization of indocyanine green dye in aging primate and human ocular tissues with clinical angiographic correlation [J].
Chang, AA ;
Morse, LS ;
Handa, JT ;
Morales, RB ;
Tucker, R ;
Hjelmeland, L ;
Yannuzzi, LA .
OPHTHALMOLOGY, 1998, 105 (06) :1060-1068
[4]  
Choudhary R, 2017, J CURR OPHTHALMOL, V29, P7, DOI 10.1016/j.joco.2016.09.009
[5]   Tocotrienols: A Family of Molecules with Specific Biological Activities [J].
Comitato, Raffaella ;
Ambra, Roberto ;
Virgili, Fabio .
ANTIOXIDANTS, 2017, 6 (04)
[6]   Mechanisms of macular edema: Beyond the surface [J].
Daruich, Alejandra ;
Matet, Alexandre ;
Moulin, Alexandre ;
Kowalczuk, Laura ;
Nicolas, Michael ;
Sellam, Alexandre ;
Rothschild, Pierre-Raphael ;
Omri, Samy ;
Gelize, Emmanuelle ;
Jonet, Laurent ;
Delaunay, Kimberley ;
De Kozak, Yvonne ;
Berdugo, Marianne ;
Zhao, Min ;
Crisanti, Patricia ;
Behar-Cohen, Francine .
PROGRESS IN RETINAL AND EYE RESEARCH, 2018, 63 :20-68
[7]   Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the AVASTIN™ Fab [J].
Fuh, G ;
Wu, P ;
Liang, WC ;
Ultsch, M ;
Lee, CV ;
Moffat, B ;
Wiesmann, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (10) :6625-6631
[8]   Early effects of systemic and intravitreal bevacizumab (Avastin®) therapy for neovascular age-related macular degeneration [J].
Geitzenauer, W. ;
Michels, S. ;
Prager, F. ;
Kornek, G. ;
Vormittag, L. ;
Rosenfeld, P. ;
Schmidt-Erfurth, U. .
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2006, 223 (10) :822-827
[9]  
Hillier R. J., 2016, RETINA, V37, P761
[10]   ANGIOPOIETIN-LIKE 4 CORRELATES WITH RESPONSE TO INTRAVITREAL RANIBIZUMAB INJECTIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION [J].
Kim, Jong Ho ;
Shin, Jae Pil ;
Kim, In Taek ;
Park, Dong Ho .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (03) :523-530